{'fraction_non_alphanumeric': 0.0341047503045067, 'fraction_numerical': 0.007308160779537149, 'mean_word_length': 6.472727272727273, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Effect of Simvastatin on markers of triglyceride‐rich lipoproteins in familial hypercholesterolaemia

Background We have previously shown elevated fasting plasma concentrations of intestinal remnants, as reflected by apolipoprotein (apo) B‐48 and remnant‐like particle‐cholesterol (RLP‐C) in patients with heterozygous familial hypercholesterolaemia (FH). We now investigate the effect of an HMG‐CoA reductase inhibitor (simvastatin) on chylomicron remnant metabolism using the measurement of fasting apoB‐48 and RLP‐C in FH patients after long‐ and short‐term simvastatin therapy and after a wash‐out period. We also piloted the response of a breath test, involving the measurement of the fractional catabolic rate (FCR) of an intravenously injected chylomicron remnant‐like emulsion labeled with cholesteryl 13C‐oleate.